Vertex Pharmaceuticals (VRTX) Long-Term Investments (2016 - 2026)

Vertex Pharmaceuticals' Long-Term Investments history runs 7 years deep, the most recent figure standing at $5.7 billion for Q1 2026.

• In Q1 2026, Long-Term Investments rose 11.51% year-over-year to $5.7 billion; the TTM figure through Mar 2026 stood at $5.7 billion (up 11.51% YoY), while the FY2025 annual figure was $5.7 billion, up 11.83% from the prior year.
• Long-Term Investments was $5.7 billion for Q1 2026 at Vertex Pharmaceuticals, up from $5.7 billion in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $5.7 billion in Q1 2026 to a low of $112.2 million in Q4 2022.
• Historically, Long-Term Investments has averaged $3.8 billion across 5 years, with a median of $4.5 billion in 2024.
• The sharpest annual moves came in 2023 and 2026: Long-Term Investments jumped 2126.2% in 2023, then climbed 11.51% in 2026.
• A 5-year view of Long-Term Investments shows it stood at $112.2 million in 2022, then surged by 2126.2% to $2.5 billion in 2023, then soared by 104.5% to $5.1 billion in 2024, then rose by 11.83% to $5.7 billion in 2025, then gained by 0.66% to $5.7 billion in 2026.
• The last three Long-Term Investments figures came in at $5.7 billion (Q1 2026), $5.7 billion (Q4 2025), and $5.7 billion (Q3 2025), per Business Quant data.